Invention Grant
- Patent Title: RNAi modulation of the BCR-ABL fusion gene and uses thereof
- Patent Title (中): BCR-ABL融合基因的RNAi调控及其用途
-
Application No.: US12510128Application Date: 2009-07-27
-
Publication No.: US07994307B2Publication Date: 2011-08-09
- Inventor: Philipp Hadwiger , Hans-Peter Vornlocher , Heiko Van Der Kuip
- Applicant: Philipp Hadwiger , Hans-Peter Vornlocher , Heiko Van Der Kuip
- Applicant Address: US MA Cambridge
- Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Fenwick & West LLP
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C07H21/02 ; A61K48/00
Abstract:
The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.
Public/Granted literature
- US20100234446A1 RNAi Modulation of the BCR-ABL Fusion Gene and Uses Thereof Public/Granted day:2010-09-16
Information query
